Written questions by Fortune.

Innovation and Technology, what discussions he had with the Economic and Social Research Council on the AI Opportunities Action Plan before its publication.

The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier. UKRI representatives, including research councils, have been engaged throughout the development of the AI Opportunities Action Plan. We are committed to working closely with the UKRI who are a critical delivery partner for key elements of the Action plan. We will continue to engage widely across the AI ecosystem as government takes the Action Plan forward.

Innovation and Technology, what discussions he had with the Government Office for Technology Transfer on the AI Opportunities Action Plan before its publication.

The Secretary of State for Science, Innovation and Technology engaged in numerous discussions with various stakeholders and government departments as part of the broader effort to ensure the AI Opportunities Action Plan, which was developed by Matt Clifford, was comprehensive and aligned with the government’s ambition for growth. The Government Office for Technology Transfer plays a crucial role in accelerating government innovations towards the market, driving growth, and delivering new products and services for citizens. As Government takes the Plan forward it will continue to engage widely.

Innovation and Technology, what discussions he had with the Science and Technology Facilities Council on the AI Opportunities Action Plan before its publication.

The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier. UKRI representatives, including research councils, have been engaged throughout the development of the AI Opportunities Action Plan. We are committed to working closely with the UKRI who are a critical delivery partner for key elements of the Action plan. We will continue to engage widely across the AI ecosystem as government takes the Action Plan forward.

Innovation and Technology, what discussions he had with Horizon Europe on the AI Opportunities Action Plan before its publication.

The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier.The Action Plan was informed by a series of external roundtables with experts from across the AI ecosystem including civil society, academia, investors, and industry, including from UKRI. The department also regularly engages with the Horizon Programme and the responsible EU officials. These discussions have informed the action plan and continue to shape our ongoing work.

Innovation and Technology, what discussions he had with the UKRI on the AI Opportunities Action Plan before its publication.

The AI Opportunities Action Plan, which was developed by Matt Clifford, sets out how we will achieve our AI ambitions by laying the foundations for AI growth, driving adoption and building UK capability at the frontier. UKRI representatives, including research councils, have been engaged throughout the development of the AI Opportunities Action Plan. We are committed to working closely with the UKRI who are a critical delivery partner for key elements of the Action plan. We will continue to engage widely across the AI ecosystem as government takes the Action Plan forward.

Innovation and Technology, whether he has had discussions with businesses on the UK's approach to supporting research into (a) detecting, (b) preventing and (c) removing child sexual abuse images created by generative Artificial Intelligence since July 2024.

The government has regular meetings with research and business organisations on matters relating to online safety and AI. The Online Safety Act places duties on platforms to proactively detect, prevent and remove child sexual abuse material (CSAM), including CSAM content created using AI technology. Ofcom has set out steps providers can take for these duties in draft codes of practice and will develop these iteratively. These steps include measures to detect, prevent and remove CSAM. The Act requires Ofcom to consult extensively when drafting its codes and Ofcom has an ongoing programme of research. The first code is due to come into force in Spring 2025.

Innovation and Technology, whether he has had discussions with universities on the UK's approach to supporting research into (a) detecting, (b) preventing and (c) removing child sexual abuse images created by generative Artificial Intelligence since July 2024.

The government has regular meetings with research and business organisations on matters relating to online safety and AI. The Online Safety Act places duties on platforms to proactively detect, prevent and remove child sexual abuse material (CSAM), including CSAM content created using AI technology. Ofcom has set out steps providers can take for these duties in draft codes of practice and will develop these iteratively. These steps include measures to detect, prevent and remove CSAM. The Act requires Ofcom to consult extensively when drafting its codes and Ofcom has an ongoing programme of research. The first code is due to come into force in Spring 2025.

Innovation and Technology, whether he has had discussions with UK Research and Innovation on their approach to supporting research into (a) detecting, (b) preventing and (c) removing child sexual abuse images created by generative Artificial Intelligence since July 2024.

The government has regular meetings with research and business organisations on matters relating to online safety and AI. The Online Safety Act places duties on platforms to proactively detect, prevent and remove child sexual abuse material (CSAM), including CSAM content created using AI technology. Ofcom has set out steps providers can take for these duties in draft codes of practice and will develop these iteratively. These steps include measures to detect, prevent and remove CSAM. The Act requires Ofcom to consult extensively when drafting its codes and Ofcom has an ongoing programme of research. The first code is due to come into force in Spring 2025.

Innovation and Technology, if he will make an assessment of the adequacy of the accessibility of the call for evidence on DSIT Central Statistics User Engagement Exercise, published on 18 December 2024.

The Department for Science, Innovation and Technology launched the call for evidence ‘DSIT Central Statistics User Engagement Exercise’ on GOV.UK on 18 December 2024, with more information available at the following link:https://www.gov.uk/government/calls-for-evidence/dsit-central-statistics-user-engagement-exerciseAs per the Government’s Publishing Accessible Documents guidance, the user engagement exercise document is published in HTML format to make it easier to read and to find. The digital survey for users to respond to the consultation is hosted on an accessible platform. The option to respond directly via email is also provided.Users who have queries on the user engagement exercise were invited to contact statistics@dsit.gov.uk

Innovation and Technology, whether he has had discussions with Horizon Europe on opportunities for research into (a) detecting, (b) preventing and (c) removing child sexual abuse images created by generative Artificial Intelligence since July 2024.

The government has regular meetings with research and business organisations on matters relating to online safety and AI. The Online Safety Act places duties on platforms to proactively detect, prevent and remove child sexual abuse material (CSAM), including CSAM content created using AI technology. Ofcom has set out steps providers can take for these duties in draft codes of practice and will develop these iteratively. These steps include measures to detect, prevent and remove CSAM. The Act requires Ofcom to consult extensively when drafting its codes and Ofcom has an ongoing programme of research. The first code is due to come into force in Spring 2025.

Innovation and Technology, what assessment he has made of the adequacy of AI regulation in (a) detecting, (b) preventing, and (c) removing child sexual abuse images created by generative artificial intelligence.

AI generated child sexual abuse images are illegal material. It is an offence to produce, store or share any material that contains or depicts child sexual abuse, regardless of whether the material depicts a real child or not.The government engages regularly with the tech sector, including AI companies, to support them in making their platforms safer for children.

Innovation and Technology, what discussions he has had with the Regulatory Innovation Office on (a) detecting, (b) preventing, and (c) removing child sexual abuse images created by generative artificial intelligence since July 2024.

The government has regular meetings with research and business organisations on matters relating to online safety and AI. The Online Safety Act places duties on platforms to proactively detect, prevent and remove child sexual abuse material (CSAM), including CSAM content created using AI technology. Ofcom has set out steps providers can take for these duties in draft codes of practice and will develop these iteratively. These steps include measures to detect, prevent and remove CSAM. The Act requires Ofcom to consult extensively when drafting its codes and Ofcom has an ongoing programme of research. The first code is due to come into force in Spring 2025.

Innovation and Technology, if he will make an assessment of the adequacy of the accessibility of the consultation on Copyright and Artificial Intelligence, published on 17 December 2024.

The Intellectual Property Office launched the ‘Copyright and Artificial Intelligence Consultation’ on 17th December 2024. As per the Governments Publishing Accessible Documents guidance, the document is published in HTML format, making it easier for users to find and navigate. The survey for users to respond to is also hosted on an accessible platform. We provided a PDF version, as per Government guidance on publishing official documents. The summary of responses is in open format (Government standard) complying with accessibility guidelines and providing ease of use. As with all of our publications, users can request an alternative format by emailing information@ipo.gov.uk.

Innovation and Technology, what discussions he has had with the Government Office for Technology Transfer on (a) detecting, (b) preventing, and (c) removing child sexual abuse images created by generative artificial intelligence since July 2024.

The Secretary of State has not had any conversations with the Government Office for Technology Transfer (GOTT) on this topic. The Home Office are responsible for policy related to detecting, preventing, and removing child sexual abuse images created by generative digital AI and Ofcom are responsible for implementing measures in the Online Safety Act 2023 that relate to detecting, preventing, and removing child sexual abuse images created by generative digital AI. GOTT helps to accelerate government’s innovations towards the market to impact growth and deliver new products and services for citizens. GOTT provides direct practical expert support, grant funding for specific opportunities, access to networks, and guidance to central government departments and arm’s length bodies.

Innovation and Technology, whether he plans to produce a domestic research strategy for (a) detecting, (b) preventing and (c) removing child sexual abuse images created by generative Artificial Intelligence.

The government has regular meetings with research and business organisations on matters relating to online safety and AI. The Online Safety Act places duties on platforms to proactively detect, prevent and remove child sexual abuse material (CSAM), including CSAM content created using AI technology. Ofcom has set out steps providers can take for these duties in draft codes of practice and will develop these iteratively. These steps include measures to detect, prevent and remove CSAM. The Act requires Ofcom to consult extensively when drafting its codes and Ofcom has an ongoing programme of research. The first code is due to come into force in Spring 2025.

Innovation and Technology, how much Government funding there was into haemophilia research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

Innovation and Technology, how much Government investment in myelodysplastic syndrome research was in 2023-24; and which public bodies provided that investment.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

Innovation and Technology, how much funding the Government provided for research into Hodgkin lymphoma in the 2023-24 financial year; and through which public bodies that funding was provided.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

Innovation and Technology, how much Government funding there was into sickle cell research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

Innovation and Technology, how much Government funding there was into vitamin B12 deficiency research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.